Market Neuron Logo
โš  Disclaimer: This report is generated using AI tools and is for informational purposes only. It does not constitute investment advice. Please consult a registered financial advisor before making any investment decisions.

VMM - Investment Analysis

Last Updated Time : 02 Aug 25, 12:58 am

Back to Investment List

Investment Rating: 2.8

๐Ÿงพ Fundamental Analysis of Valiant Laboratories Ltd (VMM)

โœ… Strengths

Strong Institutional Interest

FII Hold โ†‘ 5.82%, DII Hold โ†‘ 15.1% โ€” significant institutional accumulation

Momentum & Technical Strength

MACD: +2.38, RSI: 54.2 โ€” neutral-to-bullish setup

Price above both DMA 50: โ‚น131 and DMA 200: โ‚น119 โ€” positive trend

52W Index: 85.7% โ€” strong yearly performance

Moderate Leverage

Debt-to-Equity: 0.27 โ€” manageable capital structure

โš ๏ธ Concerns

Extremely High Valuation

P/E: 101 vs Industry PE: 63.7 โ€” highly overvalued

PEG Ratio: 2.14 โ€” expensive relative to growth

Book Value: โ‚น13.9 vs Price: โ‚น137 โ€” ~10x book, premium pricing

Weak Profitability

ROE: 10.5%, ROCE: 13.1% โ€” below ideal for long-term compounding

EPS: โ‚น1.37 โ€” low earnings base

Earnings Volatility

PAT Qtr: โ‚น115 Cr vs โ‚น263 Cr โ€” sharp sequential decline

Qtr Profit Var: +88% โ€” volatile earnings, possibly one-off gains

No Dividend Yield โ€” not suitable for income investors

๐Ÿ“‰ Ideal Entry Price Zone

Entry Zone: โ‚น115โ€“โ‚น125

Near DMA 200 and below current price

Offers better valuation comfort and trend support

๐Ÿงญ Long-Term Investment Outlook

VMM is a speculative candidate for long-term investment, driven more by momentum and institutional interest than by core fundamentals. Its valuation is stretched, and profitability metrics are modest.

Holding Period: 1โ€“2 years (shorter horizon recommended)

Reassess if ROE improves to 15%+ and PEG drops below 1.5

Monitor earnings consistency and margin trends

๐Ÿšช Exit Strategy (If Already Holding)

Partial Exit Zone: โ‚น140โ€“โ‚น145

Near 52-week high and valuation ceiling

Full Exit

If ROE stagnates below 10% for 2+ quarters

If PEG remains above 2.0 without earnings acceleration

If price breaks below โ‚น120 and fails to recover

Reinvest: Only on dips near โ‚น115 if fundamentals improve and valuation cools

Would you like a comparison with other mid-cap pharma or specialty chemical players to explore stronger long-term bets in the same space?

Edit in a page

Back to Investment List